Andersen 1994 (2121. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25: 1099–1104, doi: 10.1161/01.STR.25.6.1099. https://doi.org/10.1161/01.STR.25.6.1099...
) |
Citalopram (33); Placebo (33) |
67.0 |
60.6% |
DSM-III-R; HAMD (17 items) >12 |
6 weeks |
HAMD (17 items) |
Chen 2002 (2222. Chen W, Wang G, Chen X, Sheng Y, Zhu H. Effects of paroxetine on function recovery in patients with poststroke depression. Chin J Clin Rehabilit 2002; 13: 2014–2015.) |
Doxepin (24); Paroxetine (24); Placebo (24) |
not stated |
not stated |
Classification and diagnostic criteria of psychosis in China |
8 weeks |
HAMD (17 items) |
Fruehwald 2003 (2323. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression: a three months double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003; 250: 347–351, doi: 10.1007/s00415-003-1014-3. https://doi.org/10.1007/s00415-003-1014-...
) |
Fluoxetine (28); Placebo (26) |
64.4 |
42.0% |
Psychiatric interview, HAMD (17 items) >15 |
12 weeks |
HAMD (17 items) |
Karaiskos 2012 (2424. Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci 2012; 24: 349–353, doi: 10.1176/appi.neuropsych.11110325. https://doi.org/10.1176/appi.neuropsych....
) |
Citalopram (20); Duloxetine (20); Sertraline (20) |
52.6 |
not stated |
DSM-IV |
12 weeks |
HAMD |
Li 2008 (2525. Li LT, Wang SH, Ge HY, Chen J, Yue SW, Yu M. The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med 2008; 14: 841–846, doi: 10.1089/acm.2008.0010. https://doi.org/10.1089/acm.2008.0010...
) |
Fluoxetine (60); Placebo (30) |
68.7 |
53.3% |
HAMD (17 items) >20 |
8 weeks |
HAMD (17 items) |
Lipsey 1984 (2626. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984; 1: 297–300, doi: 10.1016/S0140-6736(84)90356-8. https://doi.org/10.1016/S0140-6736(84)90...
) |
Nortriptyline (17); Placebo (22) |
60.9 |
35.3% |
DSM-III |
6 weeks |
HAMD (17 items) |
Murray 2005 (2727. Murray V, von Arbin M, Bartfai A, Berggren AL, Landtblom AM, Lundmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005; 66: 708–716, doi: 10.4088/JCP.v66n0606. https://doi.org/10.4088/JCP.v66n0606...
) |
Sertraline (62); Placebo (61) |
70.7 |
52.0% |
DSM-IV, MADRS ≥10 |
6 weeks |
MADRS |
Ponzio 2001 (2828. Ponzio F, Marini G, Riva E. The efficacy of paroxetine in some kinds of “critical” patients. Eur Neuropsychopharmacol 2001; 11 (Suppl 2): S49-S50 (Abstract P.1.29).) |
Paroxetine (112); Placebo (117) |
65.0 |
45.4% |
MADRS ≥18 |
8 weeks |
MADRS |
Raffaele 1996 (2929. Raffaele R, Rampello L, Vecchio I, Tornali C, Malaguarnera M. Trazodone therapy of the poststroke depression. Arch Gerontol Geriatr 1996; 22 (Suppl 1): 217–220, doi: 10.1016/0167-4943(96)86939-1. https://doi.org/10.1016/0167-4943(96)869...
) |
Trazodone (11); Placebo (11) |
70.0 |
40.9% |
DSM-III-R |
45 days |
ZDS |
Reding 1986 (3030. Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, McDowell FH. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol 1986; 43: 763–765, doi: 10.1001/archneur.1986.00520080011011. https://doi.org/10.1001/archneur.1986.00...
) |
Trazodone (11); Placebo (6) |
68.0 |
29.4% |
DSM-III |
32 days |
ZDS |
Robinson 2000 (3131. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157: 351–359, doi: 10.1176/appi.ajp.157.3.351. https://doi.org/10.1176/appi.ajp.157.3.3...
) |
Fluoxetine (23); Nortriptyline (16); Placebo (17) |
62.7 |
44.6% |
DSM-IV, HAMD (28 items) ≥12 |
12 weeks |
HAMD (28 items) |
Tzavellas 2010 (3232. Tzavellas E, Karaiskos D, Spengos K, Economou E, Papadimitriou GN, Liappas I, et al. Duloxetine versus sertraline in the treatment of post-stroke depression. Eur Neuropsychopharmacol 2010; 20 (Suppl 3): S387 (Abstract P.2.c.034), doi: 10.1016/S0924-977X(10)70549-6. https://doi.org/10.1016/S0924-977X(10)70...
) |
Duloxetine (15); Sertraline (15) |
58.6 |
30.0% |
not stated |
12 weeks |
HAMD (21 items) |
Wiart 2000 (3333. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31: 1829–1832, doi: 10.1161/01.STR.31.8.1829. https://doi.org/10.1161/01.STR.31.8.1829...
) |
Fluoxetine (16); Placebo (15) |
67.6 |
51.6% |
ICD-10 |
45 days |
MADRS |
Ye 2006 (3434. Ye L, Wang Y, Wang H, Liang D. Effect of Paxil and berhomine on poststroke anxiety-depression and neurological recovery. Chin J Clin Rehabilit 2006; 6: 153–155.) |
Paroxetine (30); Imipramine (30) |
57.5 |
33.3% |
HAMD (24 items) >21 |
12 weeks |
HAMD (24 items) |